Abstract:Inherited retinal dystrophies (IRDs) display remarkable genetic heterogeneity, with over 300 retinal disease genes mapped and/or identified. Profound vision loss and blindness, often from birth, is a common occurrence in these clinically heterogeneous disease conditions. The therapeutic options for IRDs are currently very limited but recent advancements in understanding mechanisms of retinal degeneration and technological progress paved the way towards development of novel therapies. Much progress has been made in moving from gene discovery to gene therapy. However, the genetic heterogeneity of IRDs represents a significant challenge for development of gene therapy. Many studies from our group have demonstrated that the survival of cones (responsible for diurnal and high‐resolution vision) depends on the presence of rods (responsible for vision at low light levels) that secrete a diffusible trophic factor identified as rod‐derived cone viability factor (RdCVF). The discovery of RdCVF, of its receptor and mechanism of action, and the demonstration of its mutation‐independent therapeutic potential in several animal models of IRDs paved the way to the development (with the start‐up company Sparing Vision) of RdCVF neuroprotective gene therapy that entered in clinical trial in 2023. IRDs destroy photoreceptors but leave intact and functional a significant number of inner retinal cells. Using viral vectors, light‐sensitive microbial opsins can be expressed in these remaining cells, making possible their conversion into ‘artificial photoreceptors’. Our group in Paris, together with Botond Roska (IOB, Basel) and the biotech company GenSight, demonstrated that this technology, named optogenetics, can restore vision in secondary retinal neurons which can survive years after the degeneration of photoreceptors. Our groups established the foundation for the first‐in‐man clinical trial (NCT03326336) with the photoactivatable optogene ChrimsonR (developed by Ed Boyen at MIT) delivered in the eye via adeno‐associated viral vectors and electronic goggles to intensify the light and provide adaptation. We demonstrated ( Nat Med 2021 ) that optogenetics is a remarkably effective way to restore partial vision and provide useful vision restoration in blind people. Gene‐independent approaches such as neuroprotection and optogenetics would allow for the treatment of a broad spectrum of retinal dystrophies, even at advanced stages of disease, giving hope for vision rescue and vision restoration to approximately 2 million people with IRDs worldwide.

Gene therapy for RAB28: What can we learn from zebrafish?

The zebrafish eye—a paradigm for investigating human ocular genetics

Use of Zebrafish Models to Boost Research in Rare Genetic Diseases

Cost-effective strategies to knock down genes of interest in the retinas of adult zebrafish

Zebrafish in understanding molecular pathophysiology, disease modeling, and developing effective treatments for Rett syndrome

The Zebrafish As a Model for Human Disease

Generation of Zebrafish Models of Human Retinitis Pigmentosa Diseases Using CRISPR/Cas9-Mediated Gene Editing System

Drug Screening to Treat Early-Onset Eye Diseases: Can Zebrafish Expedite the Discovery?

A CRISPR-Cas9-mediated F0 screen to identify pro-regenerative genes in the zebrafish retinal pigment epithelium

An Overview towards Zebrafish Larvae as a Model for Ocular Diseases

Studying the morphology, composition and function of the photoreceptor primary cilium in zebrafish

Developing gene‐independent approaches for retinal dystrophies

Notch Inhibition Promotes Regeneration and Immunosuppression Supports Cone Survival in a Zebrafish Model of Inherited Retinal Dystrophy

Gene-Based Therapeutics for Inherited Retinal Diseases

Single cell transcriptome analyses of the developing zebrafish eye— perspectives and applications

Development of a high-throughput tailored imaging method in zebrafish to understand and treat neuromuscular diseases

Effective targeted gene ‘knockdown’ in zebrafish

Gene augmentation therapy to rescue degenerative photoreceptors in a Cwc27 mutant mouse model

Zebrafish patient avatars in cancer biology and precision cancer therapy

Zebrafish ( ) mutants provide a preclinical model for macular corneal dystrophy

Rare Genetic Blood Disease Modeling in Zebrafish